- Trials with a EudraCT protocol (2)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
2 result(s) found for: Sterile alpha motif.
Displaying page 1 of 1.
EudraCT Number: 2014-001893-32 | Sponsor Protocol Number: GLPG1205-CL-211 | Start Date*: 2015-01-19 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe U... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) BE (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020448-37 | Sponsor Protocol Number: ENC-0303-CL-203 | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Enceladus Pharmaceuticals | |||||||||||||
Full Title: Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative ... | |||||||||||||
Medical condition: Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
